Early molecular response in East African Philadelphia chromosome-positive chronic myeloid leukaemia patients treated with Imatinib and barriers to access treatment

Abstract

Background Data about haematologic malignancies from Tanzania are sparse. African studies show that chronic myeloid leukaemia (CML) is the most common leukaemia, and registry data display a lower mean age at diagnosis. Prognosis is generally good with tyrosine kinase inhibitors, but the molecular response of Imatinib treatment has never been studied in East Africa, and the outcome remains unknown. This study assessed the early molecular response (MR) as a predictor for long-term outcome and barriers to access treatment. Methods A case series of patients with CML from Northern Tanzania documented demographics and laboratory and clinical findings at diagnosis and after 3 months. The regression analysis has been performed on early MR and clinical and demographic variables using the χ2-test. The barriers of potential treatments have been assessed. Results A total of 30 patients have been analysed. The mean age was 41 years. All patients had splenomegaly, whereas 16 had hepatomegaly. Complete haematologic response was achieved in 16 and early MR in 9 patients. Hepatomegaly was positively correlated with unfavourable early MR. The average kilometre from home to hospital was 282 km (5–1,158 km). Travel expenses and time investments pose an impediment to treatment. Conclusion Patients are younger, and early MR rates are lower compared to other studies. The finding of hepatomegaly as a risk factor for unfavourable early MR was described previously in West Africa. Adherence to therapy is high in the first months of treatment. Furthermore, research is needed to understand the poor MR and the common presentation of hepatomegaly. Outreach clinics might be a solution to reduce impediments to treatment.

Artificial Intelligence Assisted Pharmacophore Design for Philadelphia Chromosome-Positive Leukemia with Gamma-Tocotrienol: A Toxicity Comparison Approach with Asciminib

“…The mechanisms of action and toxicity of the medications used to treat CML differ. In a study conducted by Oliver Henke et al [ 18 ]: it was observed that Imatinib’s utilization in the management of CML radically altered the way this disease was addressed and spurred the advent of additional potent targeted protein kinase inhibitors. FDA-approved drugs for initial therapy comprise imatinib as an initial treatment.…”

sVCAM-1, and TGFβ1 in chronic phase, chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

“…The median age at diagnosis was estimated to be 60 years in western countries, but the age at diagnosis in Africa and Asia was about ten years younger. 19 Besides, CML is more common in males than in females with the male/female ratio of 1.2-1.7. However, to the best of our knowledge, no studies have characterized the distribution and burden of CML worldwide.…”

Impact of Methionine Synthase Reductase Polymorphisms in Chronic Myeloid Leukemia Patients

“…In Sudan, CML incidence has increased considerably in recent years. It is the most common type of leukemia in age groups above 15 years; however, of all leukemia types, it is the second most common malignancy [ 6 , 7 ]. A recent study reported that diet and physical activities are both factors contributing to the rise of cancer [ 8 ].…”